中华儿科杂志
中華兒科雜誌
중화인과잡지
Chinese Journal of Pediatrics
2013年
12期
881-887
,共7页
全国儿童常见肾脏病诊治现状调研工作组
全國兒童常見腎髒病診治現狀調研工作組
전국인동상견신장병진치현상조연공작조
紫癜,过敏性%肾小球肾炎%临床方案%多中心研究%儿童
紫癜,過敏性%腎小毬腎炎%臨床方案%多中心研究%兒童
자전,과민성%신소구신염%림상방안%다중심연구%인동
Purpura,Schonlein-Henoch%Glomerulonephritis%Clinical protocols%Multicenter studies%Child
目的 探讨我国住院儿童紫癜性肾炎的临床特点、病理表现及治疗现状.方法 回顾性分析全国40所医院2008年7月1日至2011年6月30日收治的新发过敏性紫癜、经临床或病理确诊为紫癜性肾炎并在调查单位接受治疗的紫癜性肾炎患儿的病历资料,并填写统一的调查表,收集相关资料,病例登记表经参研单位初步汇总后,由中华医学会儿科学分会肾脏学组最终汇总,由专门数据录入人员录入和核对,并随机抽样进行数据核实,最后对儿童紫癜性肾炎的临床特点、病理表现及治疗现状进行统计分析.结果 此次调研最终符合入选条件且病例完整可供分析者共4863例患儿,其中男2935例,女1928例,男女比例为1.52∶1,6~13岁为发病高峰.4702例(96.7%)患儿于过敏性紫癜起病6个月内确诊肾损害.临床分型最常见为血尿和蛋白尿型(2831例,58.2%).其中1625例患儿行肾活检治疗,最常见肾活检指征为蛋白尿合并镜下血尿(1149例,70.7%).1448例肾活检患儿提供病理分级,以Ⅲ级和Ⅱ级为多见.4863例患儿中接受激素及其他免疫抑制剂治疗者共3677例(75.6%).最常见的治疗方案为单用激素1655例(34.0%);单纯血尿型患儿(362例,56.2%)多未予特殊治疗,血尿和蛋白尿型患儿最常选择治疗方案仍为单用激素治疗.肾组织病理Ⅰ级和Ⅱ级以单用激素或联合雷公藤多甙治疗为主,病理Ⅲ级和Ⅳ级以激素+环磷酰胺+甲泼尼龙冲击治疗为主.结论 本研究调查分析了我国住院紫癜性肾炎患儿的临床诊治现状,目前多根据临床分型及参照病理分级选择治疗方案,但免疫抑制剂及非特异性治疗的选择和使用方式多样,仍有待进一步临床多中心研究结果验证并加以规范.
目的 探討我國住院兒童紫癜性腎炎的臨床特點、病理錶現及治療現狀.方法 迴顧性分析全國40所醫院2008年7月1日至2011年6月30日收治的新髮過敏性紫癜、經臨床或病理確診為紫癜性腎炎併在調查單位接受治療的紫癜性腎炎患兒的病歷資料,併填寫統一的調查錶,收集相關資料,病例登記錶經參研單位初步彙總後,由中華醫學會兒科學分會腎髒學組最終彙總,由專門數據錄入人員錄入和覈對,併隨機抽樣進行數據覈實,最後對兒童紫癜性腎炎的臨床特點、病理錶現及治療現狀進行統計分析.結果 此次調研最終符閤入選條件且病例完整可供分析者共4863例患兒,其中男2935例,女1928例,男女比例為1.52∶1,6~13歲為髮病高峰.4702例(96.7%)患兒于過敏性紫癜起病6箇月內確診腎損害.臨床分型最常見為血尿和蛋白尿型(2831例,58.2%).其中1625例患兒行腎活檢治療,最常見腎活檢指徵為蛋白尿閤併鏡下血尿(1149例,70.7%).1448例腎活檢患兒提供病理分級,以Ⅲ級和Ⅱ級為多見.4863例患兒中接受激素及其他免疫抑製劑治療者共3677例(75.6%).最常見的治療方案為單用激素1655例(34.0%);單純血尿型患兒(362例,56.2%)多未予特殊治療,血尿和蛋白尿型患兒最常選擇治療方案仍為單用激素治療.腎組織病理Ⅰ級和Ⅱ級以單用激素或聯閤雷公籐多甙治療為主,病理Ⅲ級和Ⅳ級以激素+環燐酰胺+甲潑尼龍遲擊治療為主.結論 本研究調查分析瞭我國住院紫癜性腎炎患兒的臨床診治現狀,目前多根據臨床分型及參照病理分級選擇治療方案,但免疫抑製劑及非特異性治療的選擇和使用方式多樣,仍有待進一步臨床多中心研究結果驗證併加以規範.
목적 탐토아국주원인동자전성신염적림상특점、병리표현급치료현상.방법 회고성분석전국40소의원2008년7월1일지2011년6월30일수치적신발과민성자전、경림상혹병리학진위자전성신염병재조사단위접수치료적자전성신염환인적병력자료,병전사통일적조사표,수집상관자료,병례등기표경삼연단위초보회총후,유중화의학회인과학분회신장학조최종회총,유전문수거록입인원록입화핵대,병수궤추양진행수거핵실,최후대인동자전성신염적림상특점、병리표현급치료현상진행통계분석.결과 차차조연최종부합입선조건차병례완정가공분석자공4863례환인,기중남2935례,녀1928례,남녀비례위1.52∶1,6~13세위발병고봉.4702례(96.7%)환인우과민성자전기병6개월내학진신손해.림상분형최상견위혈뇨화단백뇨형(2831례,58.2%).기중1625례환인행신활검치료,최상견신활검지정위단백뇨합병경하혈뇨(1149례,70.7%).1448례신활검환인제공병리분급,이Ⅲ급화Ⅱ급위다견.4863례환인중접수격소급기타면역억제제치료자공3677례(75.6%).최상견적치료방안위단용격소1655례(34.0%);단순혈뇨형환인(362례,56.2%)다미여특수치료,혈뇨화단백뇨형환인최상선택치료방안잉위단용격소치료.신조직병리Ⅰ급화Ⅱ급이단용격소혹연합뢰공등다대치료위주,병리Ⅲ급화Ⅳ급이격소+배린선알+갑발니룡충격치료위주.결론 본연구조사분석료아국주원자전성신염환인적림상진치현상,목전다근거림상분형급삼조병리분급선택치료방안,단면역억제제급비특이성치료적선택화사용방식다양,잉유대진일보림상다중심연구결과험증병가이규범.
Objective To retrospectively investigate the current diagnosis and treatment of children with Henoch-Schonlein purpura nephritis in hospital,to survey the application of practical evidence-based guidelines in children with Henoch-Schonlein purpura nephritis.Method A nationwide survey in 40 hospitals was conducted and data of hospitalized children diagnosed as Henoch-Schonlein purpura nephritis for the first time during the period of 1st July 2008 to 30th June 2011 were analyzed.The collected information included age,gender,disease duration,clinical manifestations,relevant auxiliary examination results,renal biopsy,and treatment and so on.The data were collected and analyzed by the subspeciahy group of nephrology,Chinese Society of Pediatrics.Result There were 4863 hospitalized children with Henoch-Schonlein purpura nephritis from July 1,2008 to June 30,2011 in 40 hospitals.The male (n =2935) to female (n =1928) ratio was 1.52∶1,the peak incidence between 6 to 13 years old.Renal impairment occurred in 96.7% (n =4702) with 6 months from the onset of Henoch-Schonlein purpura.The most common clinical findings were proteinuria and hematuria (2831 patients,58.2%); 1448 patients received renal biopsy,subclass Ⅲ and Ⅱ were the most common histological types; 3677 patients (75.6%) were treated with corticosteroids and immunosuppressants.The most common treatment scheme was corticosteroids only (1655 patients,34.0%).More than half of the patients (362 patients,56.2%)with pure hematuria received no corticosteroids or immunosuppressants.Patients with hematuria and proteinuria always received corticosteroids only (1017 patients,35.9%).Corticosteroids with or without tripterygium glycosides were always given to the patients with subclass Ⅰ and Ⅱ in renal biopsy.The patients with subclass Ⅲ and Ⅳ were mainly treated with combination of corticosteroids,cyclophosphamide and methylprednisolone.Conclusion The incidence of purpura nephritis has increased; the duration of renal impairment had no correlation with the gender.Compared to the female,the male patients are more likely to have proteinuria.The patients with mild proteinuria also can present with severe renal histological impairment.There was no unified treatment scheme in the immunosuppressants and non-specific drugs.Multicenter randomized controlled trials (RCTs) are needed to explore and manage the treatment of purpura nephritis.